Furthermore, since NfL is a general neurodegeneration biomarker detected in many neurological disorders, it is unknown how its transdiagnostic predictors of clinical outcomes interact with or synergize outcomes with condition‐specific proteomic biomarkers. This evidence concerns the gene NEFL and nervous system disorder.